IRADIMED CORP — Form 8-K/A
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 38/100
What the filing says
IRADIMED reported Q2 2026 revenue of $20.5M (up 0.5% YoY from $20.4M), with GAAP diluted EPS of $0.41 and non-GAAP EPS of $0.46. The company declared a $0.20/share quarterly dividend (payable Aug 28, 2026) and reaffirmed full-year 2026 guidance of $91–96M revenue and $1.90–2.05 GAAP EPS ($2.09–2.24 non-GAAP). Key driver: launch of next-generation 3870 MRI-compatible IV pump (replacing 3860); management expects revenue acceleration in H2 2026 as 3870 shipments ramp and gross margin improves.
Why this rating
Flat Q2 revenue vs. YoY is underwhelming; offsetting positive is product transition tracking to plan and maintained FY guidance. Magnitude modest relative to $481M market cap.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.